SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as the community rallies around the OG meme coin, emphasizing its staying power compared to other crypto projects. With a strong focus on community-driven initiatives and meme creation, supporters are actively pushing for increased visibility and a "moonshot" listing. The overall sentiment is bullish, with community members encouraging others to "RAGE HARDER" and dismissing bearish market conditions.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

Armata Pharmaceuticals Inc

Armata Pharmaceuticals ($ARMP) is experiencing significant trading activity, marked by multiple trading halts and a wide intraday price range, driving community discussion about optimal entry and exit points. The surge appears linked to positive mid-stage trial results for its blood-infection drug, with some traders speculating about a potential short squeeze or buyout, while others caution about potential risks.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is trending following a significant earnings beat, with the community actively discussing the disconnect between the strong results and the stock's price action; some speculate about market manipulation and short positions. Despite the positive earnings, the stock experiences volatility, as investors assess its position in both the crypto and AI data center sectors. Upgrades from analysts are coming, with price targets being discussed among community members.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as traders digest news of a major hyperscaler deal for AI infrastructure, with community members speculating on the partner's identity and discussing the potential for a short squeeze. Despite positive news, some express concern over sector-wide headwinds and recent price action, while others see the dip as a buying opportunity, noting a raised price target from B. Riley.

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Applied Dna Sciences Inc

Applied DNA Sciences (BNBX) is trending due to its recent shift towards a BNB-focused digital asset treasury strategy, sparking discussions about its potential in the crypto space. The community is debating whether the company's new direction, including a significant private placement, will lead to a short squeeze or if it's simply a pump and dump scheme. High short interest and borrow fees are adding fuel to the volatility, as some see parabolic potential while others remain skeptical of the company's long-term prospects.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending downwards following its Q3 earnings report, with discussions centering on a missed EPS target attributed to a Brazilian tax dispute. While revenue growth remains solid and ad revenue is expected to double, some investors are concerned about valuation and are debating whether this is a buying opportunity or a sign of deeper issues, while others are mentioning subscriber decline as a worry.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

ARCT is trending due to recent data from its ARCT-032 cystic fibrosis trial, sparking mixed reactions in the community; while some are disappointed by the limited lung function improvement, others are optimistic about the observed mucus plug reduction and potential future catalysts like CSL royalties and possible company acquisition. Discussions revolve around the selloff being overdone, the drug's mechanism potentially working, and the potential for steady recovery.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana's stock is trending downwards due to concerns about the subprime auto lending market and its potential impact on the company, despite year-to-date gains. The community is actively discussing analyst downgrades, potential fraudulent activities, and the overall financial health of Carvana. Some investors express concerns about the company's valuation and business model, while others anticipate a short squeeze or earnings manipulation.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards, with community members discussing a potential correction due to high valuation and government regulations impacting AI power centers. Some traders believe the stock is being manipulated by market makers, while others remain bullish, citing the company's long-term potential in AI and data centers, viewing the dip as a buying opportunity. Overall sentiment is mixed, with concerns about short-term volatility amidst broader market fears.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing volatility as traders react to news of potential export restrictions to China and fluctuating sentiments around tariffs. The market is seeing aggressive swings, with community members debating whether to buy the dip or brace for a larger correction, with some calling the market action a "scam". Discussions also revolve around potential government actions and their impact on market stability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tempus to Report Third Quarter 2025 Financial Results on November 4

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The...

Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy?

TEM's 48% surge, key FDA clearances and bold AI acquisitions set the stage for its Q3 earnings reveal.

Tempus AI Fuels Growth Through Strategic Biotech Collaborations

TEM expands its AI-driven growth with new collaborations in oncology, neurogenomics, and diagnostic innovation.

Healthtech company Tempus AI (TEM) announced a multi-year collaboration with Whitehawk Therapeutics (WHWK) on Thursday, aimed at developing the latter’s cancer treatment pipeline.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tempus.com/news/pr/tempus-announces-collaboration-with-whitehawk-therapeutics-to-advance-biomarker-driven-oncology-research/">deal</a>, Whitehawk Therapeutics will apply Tempus’ real-world dataset, including a de-identified multimodal database, to support its clinical trial designs. A de-identified multimodal database is a collection of diverse datasets, such as medical images, clinical notes, and genetic information, from which all personally identifiable information or protected health information has been removed. It is expected that Tempus’ dataset will help Whitehawk focus on the right patient population.Whitehawk’s antibody drug conjugate portfolio includes three assets designed to target proteins that are broadly expressed in high-potential cancer indications, such as lung and gynecological cancers. The collaboration is aimed at advancing research centered on these candidates.“By partnering with Tempus, our goal is to better understand the expression of our ADC protein targets to inform indication prioritization for our clinical development programs and better exploit the full potential of our pipeline,” said Whitehawk CEO Dave Lennon.<a href="https://stocktwits.com/symbol/WHWK">Whitehawk shares</a> soared 23% on Thursday afternoon at the time of writing, while <a href="https://stocktwits.com/symbol/TEM">Tempus shares</a> dropped about 0.5%.On Stocktwits, retail sentiment around WHWK jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:590/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_16_at_12_26_39_PM_png_87d1a96f13.webp" alt="WHWK's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits" width="590" height="61"><figcaption>WHWK's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits</figcaption></figure>Retail sentiment around TEM, however, stayed within the ‘bearish’ territory, accompanied by ‘low’ message volume.<figure class="image"><img style="aspect-ratio:591/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_16_at_12_29_47_PM_png_cc45006531.webp" alt="TEM's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits" width="591" height="61"><figcaption>TEM's Sentiment Meter and Message Volume as of 12:27 p.m. ET on Oct. 16, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user hopes WHWK rallies into the $4 to $5 range.<stembedurl>https://stocktwits.com/cjstocksup/message/632578934</stembedurl>Another sounded optimistic for TEM stock, citing its relationships with big pharma and strong backlog.<stembedurl>https://stocktwits.com/TICKERTUTOR/message/632569480</stembedurl>WHWK stock has dropped 18% this year, while TEM shares rose 171% during the period.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sunshine-biopharma-stock-rises-after-launch-of-generic-cholestrol-lowering-drug-by-canadian-unit/ch6p4DqR3nu">Sunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian Unit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. (Photo by Dominika Zarzycka/NurPhoto via Getty Images)

Whitehawk Therapeutics Stock Rallies 25% On Tempus AI Collaboration Deal: Retail Hopes For A Rally Toward $5 Mark

Under the deal, Whitehawk Therapeutics will apply Tempus’ real-world dataset, including, de-identified multimodal database, to support its clinical trial designs.

Equity

Under the deal, Whitehawk Therapeutics will apply Tempus’ real-world dataset, including, de-identified multimodal database, to support its clinical trial designs.


Hims & Hers Elevates Technology-Driven Healthcare Accessibility

HIMS boosts AI-led care with new technology chief, hormone therapies and a global push via its ZAVA acquisition.

Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ...

Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European...

NVDA & PLTR Driving AI in Health: Top Health IT Stocks for Q3 Earnings

NVDA and PLTR drive AI integration across healthcare, fueling optimism for Omnicell and Tempus AI's Q3 performance.

TEM Expands Partnership With Northwestern Medicine Amid AI Boom

Tempus AI deepens its collaboration with Northwestern Medicine, embedding its AI co-pilot David directly into the health system's EHR to boost clinical efficiency.

Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell?

Tempus AI sharpens its edge in precision medicine with key acquisitions, strong R&D launches, and improving financials amid rising competition.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

TEM
Tempus AI Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TEM News

TEMTempus AI Inc